Figure 2From: Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasisViral DNA count at baseline and post-baseline in patients receiving tofacitinib or placebo. For: a) CMV and b) EBV; each data point represents a measurement for an individual patient. BID, twice daily; CMV, cytomegalovirus; EBV, Epstein-Barr virus.Back to article page